Also written as Signifor
Pasireotide is a somatostatin analog. It is filed in this library under hormones & metabolism, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as Signifor.
Regulatory status
Pasireotide has an FDA-approved product on the U.S. market, marketed as Signifor under application NDA200677.
The current label is held by Recordati Rare Diseases, Inc.
From the FDA label
is a somatostatin analog indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative 1.1 Cushing's Disease SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative..Quoted from the FDA-approved prescribing information
The evidence
One source on Pasireotide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Pasireotide's FDA-approved label indicates it for acromegaly or for a growth disorder, which are assessed on this axis. These are the markers clinicians use when assessing the growth hormone axis. They are listed here so you can read about them, not as a statement that Pasireotide changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Pasireotide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides